

UG Healthcare Corporation Limited

(Incorporated in Singapore with Unique Entity No.: 201424579Z) SGX Stock Code: 41A

website: www.ughealthcarecorporation.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY U.S. PERSON.

PROPOSED PLACEMENT OF 7,500,000 ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT THE PLACEMENT PRICE OF S\$2.545

- ALLOTMENT AND ISSUE OF NEW SHARES

1. INTRODUCTION

The Board of Directors (the "Board" or "Directors") of UG Healthcare Corporation Limited (the "Company") refers to the announcements dated 18 August 2020 in relation to the proposed placement of up to 7,500,000 fully paid-up ordinary shares in the capital of the Company at the placement price of S\$2.545 pursuant to the placement agreement entered into between the Company, CGS-CIMB Securities (Singapore) Pte. Ltd. and SAC Capital Private Limited (the "Proposed Placement"), 21 August 2020 in relation to the completion of the Proposed Placement and 26 August 2020 in relation to the receipt of the listing and quotation notice (the "LQN") (collectively, the "Previous Announcements").

Unless otherwise defined, capitalised terms used in this announcement shall have the meanings ascribed to them in the Previous Announcements.

2. ALLOTMENT AND ISSUE OF NEW SHARES

Further to the Previous Announcements, the Board is pleased to announce that, pursuant to the terms of the Share Lending Agreement, the Company had on 27 August 2020 allotted and issued 7,500,000 New Shares to the Lender, as repayment of the Loan Securities.

Following the allotment and issue of the New Shares, the total number of issued Shares of the Company increased from 196,092,856 Shares to 203,592,856 Shares. The New Shares are issued free and clear of any pledge, lien, charge security interest, encumbrance, claim, equitable interest or other third party right whatsoever and shall rank *pari passu* with the existing Shares and carry all rights similar to the existing Shares.

The New Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST from 9.00 a.m. on 31 August 2020. The LQN is not to be taken as an indication of the merits of the New Shares, the Proposed Placement, the Company, its subsidiaries and their securities.

3. CAUTIONARY STATEMENT

Shareholders and potential investors should exercise caution when trading in the shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board **UG Healthcare Corporation Limited**

Lee Keck Keong Executive Director and CEO 27 August 2020

IMPORTANT NOTICE

This announcement is for information only and does not constitute or form part of any offer to purchase, a solicitation of an offer to purchase, an offer to sell or an invitation or solicitation of an offer to sell, issue or subscribe for, securities in or into the United States or to U.S. persons (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "U.S. Securities Act")). No securities mentioned herein have been, or will be, registered under the U.S. Securities Act, or any state securities laws or other jurisdiction of the United States and no such securities may be offered or sold in or into the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act and any applicable state or local securities laws of the United States. The securities referred to in this announcement will be offered and sold only outside the United States to non-U.S. persons in accordance with Regulation S under the U.S. Securities Act. The Company does not intend to register any portion of the offering in the United States of America or to conduct a public offering of securities in the United States of America or to, or for the account or benefit of, U.S. persons.

Notification under Section 309B of the Securities and Futures Act, Chapter 289 of Singapore: The Placement Shares are "prescribed capital markets products" (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018 and "Excluded Investment Products" (as defined in MAS Notice SFA 04- N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

This announcement has reviewed by the Company's sponsor, SAC Capital Private Limited ("Sponsor)".

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Tay Sim Yee (Telephone no.: (65) 6232 3210), at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.